脉冲频率对持续流动心室辅助器件 (CF-VAD) 中的威兰德因子剪切诱导延伸的影响
Esraa Ismail1, Javier E Dominguez De Leon2,3, Jay P Sah2,3
1From the Department of Bioengineering, P. C. Rossin College of Engineering, Lehigh University, Bethlehem, Pennsylvania.
ASAIO journal (American Society for Artificial Internal Organs : 1992)
|December 29, 2025
概括
连续流动心室辅助装置 (CF-VAD) 患者由于·维勒布兰德因子 (VWF) 展开而出现出血. 在人工脉动中,较高的脉冲频率 (≥40脉冲/分钟) 显著降低了VWF延伸,可能减轻出血风险.
科学领域:
- 生物医学工程 生物医学工程
- 血液学 血液学 血液学
- 心血管科学 心血管科学
背景情况:
- 连续流动心室辅助器件 (CF-VADs) 与非手术出血增加有关.
- 在CF-VAD中失去脉动性可能会导致·威尔布兰德因子 (VWF) 解和降解,导致出血.
- 脉冲频率对VWF形状和展开的影响仍然不太清楚.
研究的目的:
- 为了研究不同脉冲频率对·维勒布兰德因子 (VWF) 形状的影响.
- 确定最佳的脉动性流量参数,以最大限度地减少CF-VAD环境中的VWF展开.
主要方法:
- 在脉动与连续流的条件下,对人类大动脉内皮细胞 (HAEC) 进行了评估,以评估VWF构造变化.
- VWF被固定在微流体装置中,并接受连续或脉动流 (20,40,60脉冲/分钟).
- 实时测量VWF延伸和反弹动态,使用阶段变化流量实验.
主要成果:
- 与HAEC的连续流相比,脉冲式流量显著减少了VWF解 (p < 0.005).
- 与连续和低频 (≤20脉冲/分钟) 流相比,40和60脉冲/分钟的频率显著降低了VWF的最大延伸.
- 连续流量导致最大的VWF最小延伸,随着脉冲频率的增加而减少.
结论:
- 优化脉动流动频率是减少VWF展开的有希望的策略.
- 较高的脉冲频率 (≥40脉冲/分钟) 在稳定VWF形状方面似乎最有效.
- 这些发现可以为减轻CF-VAD患者非手术出血的策略提供信息.
相关概念视频
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...